PIK3CA and metastatic malignant neoplasm: A Phase I trial in patients with metastatic cancer by Blagden et al. [91] studying toxicity, PK and PD of CH5132799, a pan-PI3K inhibitor particularly inhibiting PI3Kα, revealed one patient with PIK3CA-mutant clear cell carcinoma of the ovary achieving a partial response (GCIC CA125 criteria) (NCT03767335).